Preliminary results of the treatment of a mouse model of Multiple Sclerosis with Anatabine. Roskamp Institute scientists Dr. Michael Mullan and Dr. Daniel Paris used a standard model of MS (multiple sclerosis) to assess the effects of anatabine in this disease characterized by very high levels of inflammation in the brain. The mouse model known as EAE (experimental autoimmune enchephalomyelitis) is characterized by high levels of circulating antibodies to the fatty sheaths that surround nerve fibers. The model is induced by vaccinating mice with myelin which induces an autoimmune reaction. As a consequence there is a devastating inflammatory process in the brain which has the effect of destroying neurons and causing progressive paralysis. In this regard the disease model looks very similar to that which occurs in human MS. Treatment with anatabine resulted in a dramatic reduction in the rate of paralysis of hind limbs.
Dr. John L. Faessel


Commentary and Insights

Report from the Harvard Club Meeting

Dr. Mullan and the Roskamp Institute have conducted research relating to the company's anatabine compound for a number of years. Dr. Mullan first spoke to and thoroughly reprised with the supporting graphs the research that the Roskamp Institute has performed, essentially what he presented last June at a Roskamp Institute meeting. Mullan again played the videos that showed standard Alzheimer's-afflicted mice beginning not only to remember again, but becoming able to add critical new information to the cognitive equation and, thus, to change behavior so as even to improve their lot after the administration of anatabine. That's impossible for a "demented" mouse. A split screen video depicted for comparison a mouse fully impaired with the disease. He went on to say that CRP* levels also fell 50% in these test animals, indicating less inflammation. Dr. Mullan called the research "profound."  For more details of the articles please visit: